S&P 500 Testing Prior Breakout Level DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. While the dust has yet to settle, the good news is that the selloff has been largely contained to these AI-linked stocks. The rest of the market did not seem to care; the equal-weighted S&P 500 was roughly flat yesterday. Additionally, market dynamics remain healthy, with Treasury yields, the U.S. dollar (DXY), and WTI crude oil continuing to move lower, and...
Moody's Ratings (Moody's) affirmed the ratings of Johnson & Johnson ("J&J") including the Aaa long-term issuer rating, Aaa senior unsecured rating, (P)Aaa medium term note rating and Prime-1 commercial paper rating. The outlook remains stable. This rating action follows the announcement that J&J w...
A director at Johnson & Johnson maiden bought 1,000 shares at 147.220USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Titan Announces the Closing of Conavi’s Private Placement of Subscription Receipts and Provides Update on the Transaction TORONTO, Ontario, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that, in connection with its amalgamation agreement (“Amalgamation Agreement”) with Conavi Medical Inc. (“Conavi”) providing for the combination of the companies in an all-stock transaction (the “Transaction”), Conavi has closed its previously announced concurrent private placement of subscription receipts (“Subscription Receipts”) for gross pr...
Titan Announces Resignations of Directors TORONTO, Ontario, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that following its annual general meeting held on September 30, 2024 (the “Meeting”) and in accordance with Titan’s Majority Voting Policy (the “Voting Policy”), Anthony Giovinazzo, Cathy Steiner, Cary Vance and Paul Cataford have tendered to the Board of Directors (the “Board”) their resignations as directors of Titan (including Paul Cataford’s resignation as Board Chairman). Pursuant to the Voting Policy, the Corporate Governance a...
Titan Reports Voting Results from 2023 Annual General and Special Meeting TORONTO, Ontario, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announced the voting results from its Annual General and Special Meeting of Shareholders (the “AGM”) held virtually via live audio webcast on September 30, 2024. Shareholders voted in favour of all management resolutions proposed in Titan’s management information circular dated August 30, 2024 (the “Circular”). Resolutions proposed and approved at the AGM include: fixing the number of directors and election of ...
Titan Medical begins process to move to the TSX Venture Exchange TORONTO, Ontario, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that its board of directors (the “Board”) has approved the voluntary delisting (the “Delisting”) of Titan’s common shares (the “Titan Shares”) from the Toronto Stock Exchange (the “TSX”). Subject to approval by the TSX and the completion of all closing conditions for the Transaction (defined below) it is expected that the Titan Shares will be delisted from the TSX effective as of close of markets between October...
Conavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and Conavi Titan’s respective annual general and special meeting of shareholders to vote on the amalgamation transaction to take place on September 30, 2024, at 4:00 p.m. Eastern Time TORONTO, Ontario, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that Conavi Medical Inc. (“Conavi”) has received the requisite shareholder approval required to proceed with the proposed combination of Titan and Conavi (the “Amalgamation”) in an all-stock transaction (...
Proxy Deadline Thursday September 26, 2024 TORONTO, Ontario, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) released a reminder for shareholders to vote ahead of Titan’s annual and special shareholders meeting (the “Meeting”) scheduled to be held on Monday, September 30, 2024. Less than half of the Titan common shares have been voted in advance of the Meeting. VOTE TODAY. The Management Information Circular (the “Circular”) and related materials for the Meeting are available on Titan’s website at and under Titan’s SEDAR+ profile at . Fo...
Titan Announces Conavi Medical to Present Overview at Titan Q&A Session TORONTO, Ontario, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that Conavi Medical Inc. (“Conavi”) will be joining the previously announced Titan Q&A session to be held on Thursday, September 19, 2024 at 5:00 pm ET in connection with the proposed business combination between Titan and Conavi to be considered at the annual general meeting of Titan on September 30, 2024. After the Conavi presentation, Titan will provide prepared remarks followed by a Q&A session. Paul ...
Titan Announces Q&A Session with Shareholders TORONTO, Ontario, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that Titan management will host a webcast Q&A session on Thursday, September 19, 2024 at 5:00 pm ET in connection with filing and mailing of the management information circular, which was announced by press release issued on September 6, 2024. Titan will provide prepared remarks followed by a Q&A session. Paul Cataford, Interim President and CEO and Chien Huang, Chief Financial Officer will attend the session on behalf of Titan. ...
Titan Announces Filing of the Management Information Circular. TORONTO, Ontario, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce the filing and mailing of its management information circular (the “Circular”) with respect to the amalgamation agreement (“Amalgamation Agreement”) with Conavi Medical Inc. (“Conavi”) providing for the combination of the companies in an all-stock transaction (the “Transaction”). This Transaction will constitute a reverse takeover of Titan. “The Circular sets out a compelling case for shareholders to...
Titan Medical Reports Operating and Financial Results for the Second Quarter 2024 TORONTO, Ontario, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the three and six months ended June 30, 2024. Recent Activities in Q2 2024: On May 29, 2024, the Company announced an amendment to the timeframe under which certain closing conditions must be met in the amalgamation agreement dated March 17, 2024 with Conavi Medical Inc. (“Conavi”), 1000824255 Ontario Inc. (a wholly-owned subsidiary of Titan) (the “A...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.